Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 5/2016

01-10-2016 | Research Article

Patients’ knowledge and attitude towards therapeutic reference pricing system in Slovenia

Authors: Nika Marđetko, Mitja Kos

Published in: International Journal of Clinical Pharmacy | Issue 5/2016

Login to get access

Abstract

Background The therapeutic reference pricing (TRP) in Slovenia was implemented for proton pump inhibitors in 2013 and for angiotensin-converting enzyme inhibitors and lipid-lowering medicines in 2014. Objective The study aimed to assess patients’ knowledge and attitude towards the TRP system. Moreover, the patients’ willingness to pay was evaluated for patients who rejected the substitution of a current medicine within a therapeutic class by the reference medicine for which no co-payment is needed. Setting Invitation of patients to participate in a survey and filling in the first part of the questionnaire was run in the community pharmacies in Slovenia. The second part of the questionnaire was filled in at patients’ home. Method A representative sample of 676 patients that had been prescribed at least one medicine from the three therapeutic classes was surveyed. The survey was carried out from 15th May to 15th June 2014 in 40 community pharmacies with the help of the pharmacists, who filled in the first part of the questionnaire in the presence of the patients. The second part of the questionnaire was filled in by 475 patients at home and returned by prepaid mail. Main outcome measure Patients’ knowledge of and attitude to the TRP system implemented into Slovenian health care practice. Results Most of the statements describing patient’ rights and duties within the TRP system were known by approximately 50 % of the patients. Patients were inhomogeneous in their view about the necessity and benefits of the TRP system, most of them regarded it as an unnecessary burden. Among 50.4 % of the patients who were required to copay for their medicine, 46.7 % accepted and 3.7 % rejected co-payment. The average co-payment was € 6.92, while the expressed average willingness to co-pay was € 10.4 per 3 months of therapy. Conclusion Our results indicate that the implementation of the TRP system and potential upgrades represent a significant challenge for the patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Puig-Junoy J. The impact of generic reference pricing interventions in the statin market. Health Policy. 2007;84(1):14–29.CrossRefPubMed Puig-Junoy J. The impact of generic reference pricing interventions in the statin market. Health Policy. 2007;84(1):14–29.CrossRefPubMed
2.
go back to reference Vrijens F, Van de Voorde C, Farfan-Portet MI, Vander Stichele R. Patient socioeconomic determinants for the choice of the cheapest molecule within a cluster: evidence from Belgian prescription data. Eur J Health Econ. 2012;13(3):315–25.CrossRefPubMed Vrijens F, Van de Voorde C, Farfan-Portet MI, Vander Stichele R. Patient socioeconomic determinants for the choice of the cheapest molecule within a cluster: evidence from Belgian prescription data. Eur J Health Econ. 2012;13(3):315–25.CrossRefPubMed
4.
go back to reference Schneeweiss S. Reference drug programs: effectiveness and policy implications. Health Policy. 2007;81(1):17–28.CrossRefPubMed Schneeweiss S. Reference drug programs: effectiveness and policy implications. Health Policy. 2007;81(1):17–28.CrossRefPubMed
5.
go back to reference Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med. 2002;346(11):822–9.CrossRefPubMed Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med. 2002;346(11):822–9.CrossRefPubMed
10.
go back to reference Dunne SS, Shannon B, Cullen W, Dunne CP. Beliefs, perceptions and behaviours of GPs towards generic medicines. Fam Pract. 2014;31(4):467–74.CrossRefPubMed Dunne SS, Shannon B, Cullen W, Dunne CP. Beliefs, perceptions and behaviours of GPs towards generic medicines. Fam Pract. 2014;31(4):467–74.CrossRefPubMed
11.
go back to reference Heikkila R, Mantyselka P, Hartikainen-Herranen K, Ahonen R. Customers’ and physicians’ opinions of and experiences with generic substitution during the first year in Finland. Health Policy. 2007;82(3):366–74.CrossRefPubMed Heikkila R, Mantyselka P, Hartikainen-Herranen K, Ahonen R. Customers’ and physicians’ opinions of and experiences with generic substitution during the first year in Finland. Health Policy. 2007;82(3):366–74.CrossRefPubMed
12.
go back to reference Dylst P, Vulto A, Simoens S. Demand-side policies to encourage the use of generic medicines: an overview. Expert Rev Pharm Out. 2013;13(1):59–72. Dylst P, Vulto A, Simoens S. Demand-side policies to encourage the use of generic medicines: an overview. Expert Rev Pharm Out. 2013;13(1):59–72.
14.
go back to reference Quintal C, Mendes P. Underuse of generic medicines in Portugal: an empirical study on the perceptions and attitudes of patients and pharmacists. Health Policy. 2012;104(1):61–8.CrossRefPubMed Quintal C, Mendes P. Underuse of generic medicines in Portugal: an empirical study on the perceptions and attitudes of patients and pharmacists. Health Policy. 2012;104(1):61–8.CrossRefPubMed
15.
go back to reference Dunne S, Shannon B, Dunne C, Cullen W. Patient perceptions of generic medicines: a mixed-methods study. Patient. 2014;7(2):177–85.CrossRefPubMed Dunne S, Shannon B, Dunne C, Cullen W. Patient perceptions of generic medicines: a mixed-methods study. Patient. 2014;7(2):177–85.CrossRefPubMed
16.
go back to reference Himmel W, Simmenroth-Nayda A, Niebling W, Ledig T, Jansen RD, Kochen MM, et al. What do primary care patients think about generic drugs? Int J Clin Pharmacol Ther. 2005;43(10):472–9.CrossRefPubMed Himmel W, Simmenroth-Nayda A, Niebling W, Ledig T, Jansen RD, Kochen MM, et al. What do primary care patients think about generic drugs? Int J Clin Pharmacol Ther. 2005;43(10):472–9.CrossRefPubMed
17.
go back to reference Kersnik J, Peklar J. Attitudes of Slovene general practitioners towards generic drug prescribing and comparison with international studies. J Clin Pharm Ther. 2006;31(6):577–83.CrossRefPubMed Kersnik J, Peklar J. Attitudes of Slovene general practitioners towards generic drug prescribing and comparison with international studies. J Clin Pharm Ther. 2006;31(6):577–83.CrossRefPubMed
18.
go back to reference Bayoumi AM. The measurement of contingent valuation for health economics. Pharmacoeconomics. 2004;22(11):691–700.CrossRefPubMed Bayoumi AM. The measurement of contingent valuation for health economics. Pharmacoeconomics. 2004;22(11):691–700.CrossRefPubMed
20.
go back to reference Blomquist CH, Blumenshein K, Johannesson M. Eliciting willingness to pay without bias using follow-up certainty statements: comparisons between probably/definitely and a 10-point certainty scale. Environ Resour Econ. 2009;43(4):473–502.CrossRef Blomquist CH, Blumenshein K, Johannesson M. Eliciting willingness to pay without bias using follow-up certainty statements: comparisons between probably/definitely and a 10-point certainty scale. Environ Resour Econ. 2009;43(4):473–502.CrossRef
21.
go back to reference van Voorhis CRW, Morgan BL. Understanding power and rules of thumb for determining sample size. Tutor Quant Methods Psychol. 2007;3(2):43–50.CrossRef van Voorhis CRW, Morgan BL. Understanding power and rules of thumb for determining sample size. Tutor Quant Methods Psychol. 2007;3(2):43–50.CrossRef
22.
go back to reference Rathe J, Larsen P, Andersen M, Paulsen M, Jarbol D, Thomsen J, et al. Associations between generic substitution and patients’ attitudes, beliefs and experiences. Eur J Clin Pharmacol. 2013;69(10):1827–36.CrossRefPubMed Rathe J, Larsen P, Andersen M, Paulsen M, Jarbol D, Thomsen J, et al. Associations between generic substitution and patients’ attitudes, beliefs and experiences. Eur J Clin Pharmacol. 2013;69(10):1827–36.CrossRefPubMed
23.
go back to reference Heikkila R, Mantyselka P, Ahonen R. Do people regard cheaper medicines effective? Population survey on public opinion of generic substitution in Finland. Pharmacoepidemiol Drug Saf. 2011;20(2):185–91.CrossRefPubMed Heikkila R, Mantyselka P, Ahonen R. Do people regard cheaper medicines effective? Population survey on public opinion of generic substitution in Finland. Pharmacoepidemiol Drug Saf. 2011;20(2):185–91.CrossRefPubMed
25.
go back to reference Hassali MA, Alrasheedy AA, McLachlan A, Nguyen TA, Al-Tamimi SK, Ibrahim MI, et al. The experiences of implementing generic medicine policy in eight countries: a review and recommendations for a successful promotion of generic medicine use. Saudi Pharm J. 2014;22(6):491–503.CrossRefPubMed Hassali MA, Alrasheedy AA, McLachlan A, Nguyen TA, Al-Tamimi SK, Ibrahim MI, et al. The experiences of implementing generic medicine policy in eight countries: a review and recommendations for a successful promotion of generic medicine use. Saudi Pharm J. 2014;22(6):491–503.CrossRefPubMed
26.
go back to reference Kobayashi E, Karigome H, Sakurada T, Satoh N, Ueda S. Patients’ attitudes towards generic drug substitution in Japan. Health Policy. 2011;99(1):60–5.CrossRefPubMed Kobayashi E, Karigome H, Sakurada T, Satoh N, Ueda S. Patients’ attitudes towards generic drug substitution in Japan. Health Policy. 2011;99(1):60–5.CrossRefPubMed
29.
go back to reference Rathe J, Sondergaard J, Jarbol DE, Hallas J, Andersen M. Patients’ concern about their medicine after a generic switch: a combined cross-sectional questionnaire and register study. Pharmacoepidemiol Drug Saf. 2014;23(9):965–73.CrossRefPubMed Rathe J, Sondergaard J, Jarbol DE, Hallas J, Andersen M. Patients’ concern about their medicine after a generic switch: a combined cross-sectional questionnaire and register study. Pharmacoepidemiol Drug Saf. 2014;23(9):965–73.CrossRefPubMed
30.
go back to reference Toverud EL, Roise AK, Hogstad G, Wabo I. Norwegian patients on generic antihypertensive drugs: a qualitative study of their own experiences. Eur J Clin Pharmacol. 2011;67(1):33–8.CrossRefPubMed Toverud EL, Roise AK, Hogstad G, Wabo I. Norwegian patients on generic antihypertensive drugs: a qualitative study of their own experiences. Eur J Clin Pharmacol. 2011;67(1):33–8.CrossRefPubMed
31.
go back to reference Babar ZU, Stewart J, Reddy S, Alzaher W, Vareed P, Yacoub N, et al. An evaluation of consumers’ knowledge, perceptions and attitudes regarding generic medicines in Auckland. Pharm World Sci. 2010;32(4):440–8.CrossRefPubMed Babar ZU, Stewart J, Reddy S, Alzaher W, Vareed P, Yacoub N, et al. An evaluation of consumers’ knowledge, perceptions and attitudes regarding generic medicines in Auckland. Pharm World Sci. 2010;32(4):440–8.CrossRefPubMed
32.
go back to reference Bulsara C, McKenzie A, Sanfilippo F, Holman CD, Emery JE. ‘Not the full Monty’: a qualitative study of seniors’ perceptions of generic medicines in Western Australia. Aust J Prim Health. 2010;16(3):240–5.CrossRefPubMed Bulsara C, McKenzie A, Sanfilippo F, Holman CD, Emery JE. ‘Not the full Monty’: a qualitative study of seniors’ perceptions of generic medicines in Western Australia. Aust J Prim Health. 2010;16(3):240–5.CrossRefPubMed
33.
go back to reference Dylst P, Vulto A, Simoens S. The impact of reference-pricing systems in Europe: a literature review and case studies. Expert Rev Pharm Out. 2011;11(6):729–37. Dylst P, Vulto A, Simoens S. The impact of reference-pricing systems in Europe: a literature review and case studies. Expert Rev Pharm Out. 2011;11(6):729–37.
34.
go back to reference Galizzi MM, Ghislandi S, Miraldo M. Effects of reference pricing in pharmaceutical markets: a review. Pharmacoeconomics. 2011;29(1):17–33.CrossRefPubMed Galizzi MM, Ghislandi S, Miraldo M. Effects of reference pricing in pharmaceutical markets: a review. Pharmacoeconomics. 2011;29(1):17–33.CrossRefPubMed
35.
go back to reference Dylst P, Vulto A, Simoens S. Reference pricing systems in Europe: characteristics and consequences. Generics Biosimilar Initiat J. 2012;1(3–4):127–31.CrossRef Dylst P, Vulto A, Simoens S. Reference pricing systems in Europe: characteristics and consequences. Generics Biosimilar Initiat J. 2012;1(3–4):127–31.CrossRef
36.
go back to reference Analysis of the Faculty of pharmacy—assessed by data in National database on outpatient prescriptions for the year 2013–HIIS. Analysis of the Faculty of pharmacy—assessed by data in National database on outpatient prescriptions for the year 2013–HIIS.
Metadata
Title
Patients’ knowledge and attitude towards therapeutic reference pricing system in Slovenia
Authors
Nika Marđetko
Mitja Kos
Publication date
01-10-2016
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 5/2016
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-016-0370-x

Other articles of this Issue 5/2016

International Journal of Clinical Pharmacy 5/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.